Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia

Clinical trial NCT01982175 · SUSPENDED

Trial details

NCT number: NCT01982175
Sponsor: Shanghai Zhangjiang Biotechnology Limited Company
Status: SUSPENDED
Phase: Phase 2
Study type: INTERVENTIONAL

B-cell Chronic Lymphocytic Leukemia

Start date: 2011-07-01
Primary completion: 2021-02-01
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.